Study Evaluating TCH346 and Placebo Administered Once Daily in Patients With Amyotrophic Lateral Sclerosis (ALS)
Status:
Completed
Trial end date:
2004-12-01
Target enrollment:
Participant gender:
Summary
This is a global multicenter study designed to evaluate the safety and clinical effects of 4
oral doses of TCH346 (1.0, 2.5, 7.5, and 15 mg) compared to placebo in patients with mild or
mild to moderate stages of ALS. The study consists of 3 phases: screening (up to 2 weeks),
run-in (16 weeks), and a double-blind treatment phase of variable duration (at least 24
weeks).